ProCE Banner Activity

Protecting Patients With Hematologic Malignancies With COVID-19 mAbs

Clinical Thought

Patients with compromised immune systems, such as those with hematologic malignancies, are at higher risk of severe complications from COVID-19 and often develop suboptimal responses to the COVID-19 vaccine—but COVID-19 monoclonal antibodies (mAbs) provide some promise for this highly vulnerable population.

Released: May 15, 2024

Expiration: May 14, 2025

Share

Faculty

Mazyar Shadman

Mazyar Shadman, MD, MPH

Innovators Network Endowed Chair
Associate Professor of Hematology and Oncology
Lymphoid Malignancies and Immunotherapy 
Fred Hutch Cancer Center and University of Washington
Seattle, Washington

Provided by

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Partners

Clinical Care Options, LLC

ProCE Banner

Disclosure

Primary Author

Mazyar Shadman, MD, MPH

Innovators Network Endowed Chair
Associate Professor of Hematology and Oncology
Lymphoid Malignancies and Immunotherapy 
Fred Hutch Cancer Center and University of Washington
Seattle, Washington

Mazyar Shadman, MD, MPH: consultant/advisor/speaker: AbbVie, AstraZeneca, Beigene, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Genentech, Janssen, Kite Pharma, Merck, Morphosys/Incyte, Mustang Bio, Nurix; researcher: AbbVie, AstraZeneca, Beigene, Genetech, Genmab, Morphosys, Mustang Bio, Vincerx; individual publicly traded stock/stock options: Koi Biotherapeutics.